Log In
BCIQ
Print this Print this
 

LJPC-401

  Manage Alerts
Collapse Summary General Information
Company La Jolla Pharmaceutical Co.
DescriptionSynthetically derived hepcidin, an endogenous hormone that regulates iron absorption
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationAnemia
Indication DetailsTreat patients at risk of iron overload; Treat transfusion-dependent anemia and severe chronic iron overload in patients who are refractory or intolerant to chelation therapy
Regulatory Designation
PartnerInstitut National de la Sante et de la Recherche Medicale (INSERM)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today